Luke Miels - GlaxoSmithKline PLC President - Global Pharmaceuticals

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

  President
Mr. Luke Miels is the President Global Pharmaceuticals of the Company. Luke joined GSK and the CET in September 2017 as President, Global Pharmaceuticals, responsible for our commercial portfolio of medicines and vaccines. Previously, he worked for AstraZeneca as Executive Vice President of their European business and, prior to that, was Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporationrationrate Affairs. Before then, he held roles of increasing seniority at Roche and SanofiAventis in the US, Europe and Asia. He is a member of the Board for ViiV Healthcare. Luke holds a BS degree in Biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney.
  President Since 2017  MBA    
(44) 20 8047 7807  www.gsk.com

GlaxoSmithKline PLC Management Efficiency

GlaxoSmithKline PLC has Return on Asset of 7.78 % which means that on every $100 spent on asset it made $7.78 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 50.81 %, implying that it generated $50.81 on every 100 dollars invested. GlaxoSmithKline PLC management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current Return on Investment is estimated to increase to 23.20. The current Return on Average Assets is estimated to increase to 0.07GlaxoSmithKline PLC Return on Average Assets are decreasing as compared to previous years. The last year's value of Return on Average Assets was reported at 0.07. The current Tangible Assets Book Value per Share is estimated to increase to 14.38, while Goodwill and Intangible Assets are estimated to decrease to under 32.9 B. The current Total Liabilities is estimated to decrease to about 57 B. The current Current Liabilities is estimated to decrease to about 22.5 B
The company has 36.63 B in debt with debt to equity (D/E) ratio of 1.59, which is OK given its current industry classification. GlaxoSmithKline PLC has a current ratio of 0.85, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Menelas PangalosAstrazeneca PLC
2019
David ElkinsBristol Myers Squibb
2019
Alfonso ZuluetaEli Lilly And
2017
Steven MizellMerck Company
2018
Daniel SkovronskyEli Lilly And
2018
Samuel MoedBristol Myers Squibb
2012
Thomas LynchBristol Myers Squibb
2017
Katie WatsonGilead Sciences
N/A
Ann JudgeBristol Myers Squibb
2016
Emmanuel BlinBristol Myers Squibb
2016
Mark MallonAstrazeneca PLC
2016
Fionnuala WalshEli Lilly And
2007
Adele AmbroseMerck Company
2009
John ElickerBristol Myers Squibb
2020
Charles BancroftBristol Myers Squibb
2019
Paul CarterGilead Sciences
2014
Ann PowellBristol Myers Squibb
2016
Iskra ReicAstrazeneca PLC
2019
Bahija JallalAstrazeneca PLC
2013
Lafmin MorganGrifols S A
N/A
Sandra LeungBristol Myers Squibb
2015

Company Summary

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on BATS Exchange. It employs 99437 people.GlaxoSmithKline PLC (GSK) is traded on BATS Exchange in USA. It is located in 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom and employs 99,437 people. GlaxoSmithKline PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

GlaxoSmithKline PLC Leadership Team

Vindi Banga, Senior Independent Non-Executive Director
Lynn Elsenhans, Independent Non-Executive Director
Luke Miels, President - Global Pharmaceuticals
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director
Daniel Podolsky, Non-Executive Independent Director
Emma Walmsley, Chief Executive Officer, Executive Director
Luc Debruyne, President - Global Vaccines
Andrew Witty, CEO, Executive Director
Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare
Charles Bancroft, Non-Executive Director
Roy Anderson, Non-Executive Independent Director
Philip Hampton, Independent Non-Executive Director
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Vivienne Cox, Non-Executive Independent Director
Bill Louv, Senior Vice President - Core Business Services
Diana Conrad, Senior Vice President - Human Resources
Roger Connor, President - Global Manufacturing & Supply
Abbas Hussain, President Global Pharmaceuticals
Phil Thomson, Senior Vice President - Global Communications
Judy Lewent, Non-Executive Independent Director
Hans Wijers, Independent Non-Executive Director
Stephanie Burns, Non-Executive Independent Director
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Urs Rohner, Non-Executive Independent Director
Marvinder Banga, Senior Non-Executive Independent Director
Deryck Maughan, Senior Independent Non-Executive Director
Jesse Goodman, Non-Executive Independent Director
Laurie Glimcher, Non-Executive Independent Director
Nick Hirons, Senior Vice President - Global Ethics and Compliance
Sally Jackson, Senior Vice President - Global Communications and CEO Office
James Ford, Senior Vice President General Counsel
Victoria Whyte, Company Secretary
Daniel Troy, Sr. VP and General Counsel
Shah Hussain, President - Europe, Japan & EMAP
Manvinder Banga, Non-Executive Director
David Redfern, Chief Strategy Officer
Patrick Vallance, President - Pharmaceuticals R&D
Stacey Cartwright, Non-Executive Independent Director
Regis Simard, President - Pharmaceutical Supply Chain
Jonathan Symonds, Independent Non-Executive Chairman of the Board
Iain Mackay, Chief Financial Officer, Executive Director
Karenann Terrell, Chief Digital & Technology Officer
Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare
Claire Thomas, Senior Vice President - Human Resources

Stock Performance Indicators

Did you try this?

Run Analyst Recommendations Now

   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page